BACPHARPharmaceuticals
Bacil Pharma Ltd — Profit & Loss Statement
₹47.73
-1.10%
Bacil Pharma Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 83.15 | -2122.44 | — |
| Tax Rate For Calcs | 0.01 | 0.30 | 0.00 | 0.00 | — |
| Normalized EBITDA | -0.25 Cr | -0.19 Cr | -0.14 Cr | -0.10 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 0.40 Cr | -0.06 Cr | -0.10 Cr | -3.86 Cr | — |
| Reconciled Depreciation | 7000.00 | 20000.00 | 27000.00 | 37174.00 | — |
| EBITDA | -0.25 Cr | -0.19 Cr | -0.10 Cr | -3.86 Cr | — |
| EBIT | -0.25 Cr | -0.19 Cr | -0.10 Cr | -3.86 Cr | — |
| Normalized Income | 0.40 Cr | -0.06 Cr | -0.15 Cr | -0.10 Cr | — |
| Net Income From Continuing And Discontinued Operation | 0.40 Cr | -0.06 Cr | -0.10 Cr | -3.86 Cr | — |
| Total Expenses | 0.25 Cr | 0.19 Cr | 0.18 Cr | 0.16 Cr | — |
| Diluted NI Availto Com Stockholders | 0.40 Cr | -0.06 Cr | -0.10 Cr | -3.86 Cr | — |
| Net Income Common Stockholders | 0.40 Cr | -0.06 Cr | -0.10 Cr | -3.86 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 0.40 Cr | -0.06 Cr | -0.10 Cr | -3.86 Cr | — |
| Net Income Including Noncontrolling Interests | 0.40 Cr | -0.06 Cr | -0.10 Cr | -3.86 Cr | — |
| Net Income Continuous Operations | 0.40 Cr | -0.06 Cr | -0.10 Cr | -3.86 Cr | — |
| Tax Provision | 34000.00 | 1000.00 | -180.00 | -2180.00 | — |
| Pretax Income | 0.41 Cr | -0.06 Cr | -0.10 Cr | -3.86 Cr | — |
| Other Non Operating Income Expenses | 0.66 Cr | 0.13 Cr | 0.11 Cr | 0.06 Cr | — |
| Operating Income | -0.25 Cr | -0.19 Cr | -0.18 Cr | -0.16 Cr | — |
| Operating Expense | 0.25 Cr | 0.19 Cr | 0.18 Cr | 0.16 Cr | — |
| Other Operating Expenses | 0.11 Cr | 0.09 Cr | 0.08 Cr | 0.08 Cr | — |
| Depreciation And Amortization In Income Statement | 7000.00 | 20000.00 | 26920.00 | 37174.00 | — |
| Depreciation Income Statement | 7000.00 | 20000.00 | 26920.00 | 37174.00 | — |
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Total Unusual Items | — | 0.10 Cr | 0.05 Cr | -3.76 Cr | -0.17 Cr |
| Total Unusual Items Excluding Goodwill | — | 0.10 Cr | 0.05 Cr | -3.76 Cr | -0.17 Cr |
| Reconciled Cost Of Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Interest Income | — | 0.03 Cr | 0.03 Cr | 0.06 Cr | 0.07 Cr |
| Interest Expense | — | 6600.00 | 14170.00 | 8168.00 | 45604.00 |
| Interest Income | — | 0.03 Cr | 0.03 Cr | 0.06 Cr | 0.07 Cr |
| Diluted Average Shares | — | 0.59 Cr | 0.60 Cr | 0.59 Cr | 0.58 Cr |
| Basic Average Shares | — | 0.59 Cr | 0.60 Cr | 0.59 Cr | 0.58 Cr |
| Diluted EPS | — | -0.10 | -0.17 | -6.55 | -0.41 |
| Basic EPS | — | -0.10 | -0.17 | -6.55 | -0.41 |
| Special Income Charges | — | 0.00 | -27280.00 | -3.69 Cr | -0.03 Cr |
| Write Off | — | 0.00 | 27280.00 | 0.00 | 0.03 Cr |
| Net Non Operating Interest Income Expense | — | 0.03 Cr | 0.03 Cr | 0.06 Cr | 0.07 Cr |
| Total Other Finance Cost | — | 540.00 | 880.00 | 374.00 | 1074.00 |
| Interest Expense Non Operating | — | 6600.00 | 14170.00 | 8168.00 | 45604.00 |
| Interest Income Non Operating | — | 0.03 Cr | 0.03 Cr | 0.06 Cr | 0.07 Cr |
| Selling General And Administration | — | 0.01 Cr | 0.01 Cr | 0.02 Cr | 0.01 Cr |
| General And Administrative Expense | — | 0.01 Cr | 0.01 Cr | 0.02 Cr | 0.01 Cr |
| Gross Profit | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost Of Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Special Charges | — | — | — | 3.69 Cr | — |
| Research And Development | — | — | — | — | 86056.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Bacil Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.